Nu-Med Plus (NUMD) Return on Invested Capital (2017 - 2019)

Nu-Med Plus (NUMD) reported Return on Invested Capital of 0.73% for Q3 2019, down 20.6% sequentially from 0.61% in Q2 2019.

Nu-Med Plus (NUMD) Return on Invested Capital (2017 - 2019) Analysis & Trends

Nu-Med Plus (NUMD) has 3 years of Return on Invested Capital data on file, last reported at 0.73% in Q3 2019.

For the quarter ending Q3 2019, Return on Invested Capital changed N/A year-over-year to 0.73%; the trailing twelve-month figure through Sep 2019 stood at 0.73% (changed N/A YoY), and the FY2018 full-year result was 1.15%, changed N/A from the prior year.
Return on Invested Capital fell to 0.73% in Q3 2019, from 0.61% in the prior quarter.
In the past five years, Return on Invested Capital ranged from a high of 0.3% in Q4 2018 to a low of 0.73% in Q3 2019.
A 3-year average of 0.5% and a median of 0.43% in 2017 frame the typical range for Return on Invested Capital.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Abbott Laboratories	180.89 Bn	173.59 Bn	6.27 Bn	0.01%
2	Stryker	127.82 Bn	124.94 Bn	3.81 Bn	0.01%
3	Medtronic	107.49 Bn	98.27 Bn	6.41 Bn	0.01%
4	Boston Scientific	67.24 Bn	65.78 Bn	3.61 Bn	0.00%
5	Edwards Lifesciences	48.02 Bn	44.34 Bn	1.29 Bn	-
6	Dexcom	28.25 Bn	27.14 Bn	750.30 Mn	-
7	GE HealthCare Technologies	28.17 Bn	25.89 Bn	1.98 Bn	0.00%
8	Smith & Nephew	26.72 Bn	26.14 Bn	-	-
9	Koninklijke Philips	25.31 Bn	22.19 Bn	2.07 Bn	0.00%
10	Nu-Med Plus	1.67 Mn	1.67 Mn	-	-

Download Data